History

Date		Event
11/2007		GENEART is in the Deloitte Technology Fast 500 EMEA ranking.
10/2007		GENEART is honored with the “Deloitte Technology Fast 50” Award as one of the 50 fastest growing technology companies in Germany.
06/2007		GENEART is recognized as one of Bavaria’s fastest growing enterprises and receives the “BAYERNS BEST 50” business award
02/2007		To match increased demands in production, the number of employees grows to more than 100
01/2007		GENEART is awarded a contract for the production of several thousand genes by the US National Cancer Institute (part of NIH) with an order volume of USD 6.5M
12/2006		The production capacity increases to 1 million base pairs per month. The F.A.Z Institute and Infraserv Hoechst recognize GENEART with the “STEP Award”for high growth companies. The award includes € 100,000 in prize money.
11/2006		GENEART is in the Deloitte Technology Fast 500 EMEA ranking The German Federal Ministry of Education and Research (BMBF) allocates a research grant of € 1.5M to GENEART for the development of a new technology platform for the directed evolution of proteins
10/2006		GENEART is honored with the “Deloitte Technology Fast 50” Award as one of the 50 fastest growing technology companies in Germany.
06/2006		GENEART is recognized as one of Bavaria’s fastest growing enterprises and receives the “BAYERNS BEST 50” business award.
05/2006		IPO at the Entry Standard of the Frankfurt Stock Exchange
04/2006		GENEART GmbH changes to the public corporation GENEART AG
02/2006		The production capacities increases to 0.5 million base pairs per month.
11/2005		Foundation of GENEART Inc. in Canada
11/2005		GENEART is in the Deloitte Technology Fast 500 EMEA ranking.
10/2005		GENEART is honored with the “Deloitte Technology Fast 50” Award as one of the 50 fastest growing technology companies in Germany.
07/2005		GENEART welcomes the 50th employee.
01/2005		GENEART's gene synthesis process is fully DIN EN ISO 9001:2000 certified by TÜV Süd Management Service.
12/2004		GENEART becomes member of the p –Alliance together with QIAGEN, StrathmannBiotec AG and NewLabBioQuality AG for manufacturing GMP scale plasmid DNA.
11/2004		GENEART is awarded with the Potential Innovation 2004 prize by DIHK and Financial Times Deutschland.
07/2004		Multi-national HIV vaccine clinical trial (EUROVACC) uses genes produced and designed by GENEART
06/2003		GENEART wins third place of German Founders’ Award („Deutscher Gründerpreis“)
05/2003		GENEART is honored with the Young Enterprise Award of Bavaria (“Bayerischer Gründerpreis”)
09/2002		Second round of financing obtained Lead investor: equinet Venture Partners AG Co-investor: S-REFIT AG, tbg, Bayern Kapital
06/2001		Launch of proprietary gene sequence design software GeneOptimizer™
10/2000		Awarded BMBF grant (BioChance-Program) for gene synthesis project
05/2000		First Round of Financing Lead investor: S-REFIT AG Co-investor: tbg, Bayern Kapital
11/1999		Market Entry of GENEART
11/1999		Foundation of GENEART

PDF